HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC

Inclusion Criteria: The diagnosis of HCC was based on the diagnostic criteria for HCC used by the EuropeanAssociation for the Study of the Liver (EASL)

• Patients must have at least one tumor lesion that can be accurately measured accordingto EASL criteria.

• diagnosed with major or main portal vein invasion (Vp3 or Vp4)

• KPS≥70；

• with no previous treatment

• No Cirrhosis or cirrhotic status of Child-Pugh class A only

• Not amendable to surgical resection ,local ablative therapy and any other curedtreatment.

• The following laboratory parameters:

• Platelet count ≥ 75,000/µL

• Hemoglobin ≥ 8.5 g/dL

• Total bilirubin ≤ 30mmol/L

• Serum albumin ≥ 30 g/L

• ASL and AST ≤ 5 x upper limit of normal

• Serum creatinine ≤ 1.5 x upper limit of normal

• INR ≤ 1.5 or PT/APTT within normal limits

• Absolute neutrophil count (ANC) >1,500/mm3

• Ability to understand the protocol and to agree to and sign a written informed consentdocument

Exclusion Criteria:

• Evidence of hepatic decompensation including ascites, gastrointestinal bleeding orhepatic encephalopathy

• Known history of HIV

• History of organ allograft

• Known or suspected allergy to the investigational agents or any agent given inassociation with this trial.

• Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy

• Evidence of bleeding diathesis.

• Patients with clinically significant gastrointestinal bleeding within 30 days prior tostudy entry.

• Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose ofstudy drug

• Serious non-healing wound, ulcer, or bone fracture

• Known central nervous system tumors including metastatic brain disease